This is a classic message copied from this board... lol
dan279 • Mar 24, 2015 5:55 PM
Sold in the low 3s today. Got hammered on the UC PFE trial as no clear efficacy was evident with Multistem.
So why do you buy 400%??? It will more than likely drop to 80 cents again. Look at the short interest.
★ -- instead of moving along he stays on this board? Is it for public service? Nope, it's to try and get back in at a lower price because he knows he screwed up... if not it would have been time to skedaddle along to the next investment or trade.
dan279 - you get the first annual Mr. Obvious award from longs on this message board. Lol :-)
In Athersys' ongoing Phase 2 clinical study, it is evaluating the administration of MultiStem cell therapy to patients who have suffered an ischemic stroke. Based on preclinical research to date, administration of MultiStem has shown significant benefits through several mechanisms, including reduction of inflammation and immune system modulation in the ischemic area, and the protection and rescue of damaged or injured cells, including neuronal tissue. Athersys is treating patients one to two days after the stroke has occurred, in contrast to thrombolytic tPA treatment, which is limited to the first three to four hours following the stroke. Preclinical studies have demonstrated that administration of a single dose of MultiStem therapy, even one week after a stroke, provides significant and durable improvements relative to controls. Enrollment in Athersys' double-blind, placebo-controlled trial is complete, and interim safety and initial efficacy results following the ninety-day patient data are expected to be announced in April 2015, following analysis and receipt of the unblinded clinical data.
Meant pre. Clinical. Smartphone... always makes changes. Have to use periods so it won't change some words. Either it's not that smart or I'm technically challenged.
Look where they updated with the Chugai deal... then read the part about prelationships clinical studies. That's a lot of science backed evidence behind MultiStem.... I believe this indication will be a successful endeavor for Athersys.
The goal is to prevent damage and recovery early on. The 30 day area has multiple signs of success. That means at 90 days it should show better results than those who were not treated, unless a second stroke occurred.
8)The potential for share gain is easily in the $15.40 area following positive data. Not all at once, but, fast. Weeks at the most. On any additional news that's positive the share price should continue to soar higher. After a positive release for the data on ischemic stroke is released, a cascade of positive news should start. Maybe even new partnerships. $40 to $60 in a year or two is likely... examples exist.. look! More would not surprise.
9)Thomas Delvin the MD over at Erlanger is on video for all to hear and he's very positive in regards to the Athersys adult stem cells... watch and listen to the video and look at his qualifications afterwards.
10)You've done due diligence and the gap open from the Chungai partnership news was filled 100% today. YES – big money manipulates with the goal of a low entry.
1)No hurry up share offering transpired - The share price went over $3 from the sub $1.50 area and if Athersys sensed a fail – they'd be looking for money to survive. The lack of an offering is extremely bullish.
2)Athersys with partners has invested heavily in cryopreserve units and bioreactor units to both store and create viable stem cells. This was note done for the end game of “fail”.
3)Athersys CEO Gil Van Bokkelen has gone way out on a limb with positive comments ahead of this trial. He's a professional and did not make his comments without thought.
4)Chugai Pharmaceuticals invested $10 million in Athersys at a time when they could have waited out results before making that decision. Chugai employs scientists who examined MultiStems potential.
5)Big money did not decide to dump Athersys shares at the same time the entire biotech sector was down. They don't employ people to bash a stock while they are selling stock. The high number of negative posts suggests accumulation and not selling.
6)Athersys has a liver transplant trial that will also report data, Athersys fought to regain the rights to its MultiStem AMI application from Angiotech. Map3 bone grafts work, GvHD has a lot of science behind it. Athersys has the ability to consolidate and has proven to be a survivor in the past. This is not a one trick pony and Athersys does have a non stem cell side of the house. They focus on MultiStem now because the potential is great.
7)For the ischemic stroke application MultiStem looks to be well suited. This trial has a higher odds of success than it's given credit for. The ulcerative colitis trial used one dose on a chronic condition that was in a hard to treat group of patients. Athersys has updated the company profile with the Chugai deal and did not remove Pfizer as a partner for IBD? Something good may develop. One high dose of MultiStem should work in Ischemic stroke as it's not a chronic condition.
Studies point to a good 30 day improvement, why would the condition worsen at 90 days unless the patient had a second stroke. People don't 'unheal" .. lol
WST had a nice post here that disappeared along with some other replies, however, what I just posted here is the short version.
You seem to be pumping in the down direction... I post links and science while you call people names. Seems your the pumper for an attempt at personal gain. Pumping works both ways and the guilty party is none other than you... good luck with that... You shorted the wrong stock.
Biotech sold off today - Many Athersys investors did get nervous. Some may be buying back and new investors may like what they've seen in terms of a pull back making for a favorable entry point. Nobody can say if my take is correct or not. We'll all know when the data comes out. I've not sold and in fact picked up more shares... not at the low of the day. $3.09 to be exact. Started this position at $1.47
At the current prices I'm inclined to hold through the data release. If I'm wrong I'll have to live with it, that said a lot of manipulation was going on and I'll stick with my calculated risk vs the fear mongering that's going on here. Just look at all the negative posts here and know that they probably were coupled with attacks on the bid and ask as well.
Who knows if it's flippers or shorts. I for the second day in a row would have joined flippers and been successful at getting back in lower. That's hind sight and not reality in my case today.
This is not the ulcerative colitis trial - I wish all well regardless. I'll be holding all my shares as long as the price remains this low. As of today's price action - I'm committed to the outcome of this trial. Obviously the manipulators are those who bet and post against this company.
Here is what the article says: "as of this writing of ~$3.00 this represents a gain in excess of 130%. This demonstrates the pent up anticipation that exists for the results of the Phase II study of ischemic stroke. Efficacy results are measured 90 days after administration of MultiStem, using the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel Index (BI). We believe that successful Phase II could result in a 400% near term share price gain or more.:
Nowhere does it say a 400% gain from the share price of $1.30... I read it as 400% gain from the ~$3.00 mark.
Further the why not pick the old $4.33 area before UC data was released? That would mean this share price is still down.
Are we all forgetting the liver trail for transplant? What if that trial is successful is the company still going to $1... Athersys just took in $10 million from Chugai and a going concern mention in the article is a bit much.
I hope all sell who wish to play it safe... I'm holding for the big gains if the price stays low. Remember that when I'm posting after data with a smile. Good luck to you :-)
Let's not forget the liver transplant trial... that and Athersys just took in 10 million From its Japan partner. There is more evidence this trial will succeed in the lack of an offering - it kind of says --- Athersys management is NOT WORRIED ABOUT THE FUTURE.
Think about it :-)
Based on two price targets after good data... one in the Seeking Alpha article is $15 figured by the 400% upside to $3 and the other $15.40 following through with Edison's odds. The odds move to 100% good data on good data. Using those two figures $7.50 to $7.70 should be the lowest area because it's the place of an even bet. You could gain or lose an equal amount in that trade range theoretically. In reality the $7.50 to $7.70 area would still be low for an even bet ahead of data because the stock won't go to zero on a fail and the upside will have just begun at $15 on good data. Not saying $15 comes immediately, just saying the climb will ultimately be much higher. Let's see if this SA article has some bite to it come Wednesday's trading.
Agree, this article was well written and confirms that a higher market cap of at least $15 is warranted on positive data release. I've been suggesting a value of $15.40 using an odds factor and what I see as Edison's formula. The author suggests more upside with the additional pipeline and that's the same line of thinking many of us have who post on this message board.
The candles are green or white in key areas, nkl0145. I agree with you. Decent accumulation pattern and an obvious chop pattern. $3.35 is an area the manipulators are working on staying under. Once that goes the real resistance in the $3.40 - $3.45 area is much weaker after yesterday.
"So for example right now if you suffer a stroke you may be looking at long term institutional care costs that are hundreds of thousands of dollars or more over time," said Gil Van Bokkelen, chairman of the nonprofit Alliance for Regenerative Medicine in Washington, D.C. He’s also CEO of the Ohio-based bio tech firm Athersys.
Right now, he says, strokes cost this nation about $73 billion a year. Van Bokkelen says stem cell therapies can help slow the financial blood-letting.
"At the end of the day it’s really about improving clinical outcomes improving quality of life and shifting the cost curve in the right direction – providing more cost effective health care — and that’s how we’ll be able to broaden the scope of heath care accessibility to all the people we’d like to provide it to," Van Bokkelen said.
I can tell you what we all know. 6 straight trade days with a higher close. Today was a higher high and a higher close making the 6th in a row. I'm all for more days like today. My thoughts have not changed... I think Athersys shares are under valued. The fact is there were more buyers than sellers again today (hence a .07 higher close). Sure some are banking profits on daily highs and then buying back in if they can and it really makes the float smaller.
My last article at biojaxusaDOTblogspotDOTcom/ says it all. I suggest reading it again for everyone who's unsure because it has been updated several times. Decide what you want for your risk and yourself. No shares were sold on my end today because I consider this price ridiculously low given the potential.
I'd be surprised if $4 does not break soon, maybe even this week.
Draw your own conclusions.